Selonterra develops small molecule drugs targeting genetically linked mechanisms in Alzheimer’s and Parkinson’s diseases, utilizing human genetics and gene regulatory networks to identify novel therapeutic targets. By employing a precision-medicine approach, the company aims to enhance treatment efficacy and improve health outcomes for patients with neurodegenerative disorders.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Alzheimer's and Parkinson's diseases lack effective treatments that address the underlying genetic mechanisms driving neurodegeneration. Current therapeutic approaches often fail to consider the genetic diversity of patients, leading to limited efficacy and variable outcomes. Identifying and targeting novel, druggable targets within gene regulatory networks remains a significant challenge in developing disease-modifying therapies.
Solution
Selonterra is developing small molecule drugs that target genetically linked mechanisms in Alzheimer’s and Parkinson’s diseases. The company leverages human genetics and gene regulatory networks to identify novel therapeutic targets that have been previously unexploited. Their approach focuses on modulating key mediators of neurodegeneration with small molecule drugs, which are designed to enhance accessibility and convenience for patients. By applying a precision-medicine approach, Selonterra aims to improve health outcomes through rational patient selection and targeted clinical studies. Their lead compounds are designed to restore APOE4-induced gene expression dysfunction and synaptic deficits.
Target Audience
The primary target audience includes patients with Alzheimer's and Parkinson's diseases who have genetically defined subtypes of these conditions, as well as clinicians and researchers focused on neurodegenerative disorders.
Features
- Focus on genetically linked mechanisms in neurodegenerative disorders.
- Utilizes human genetics and gene regulatory networks to identify novel therapeutic targets.
- Develops small molecule modulators of key mediators of neurodegeneration.
- Employs a precision-medicine approach for targeted patient selection.
- Lead compounds designed to restore APOE4-induced gene expression dysfunction and synaptic deficits.
- Pipeline programs for Alzheimer’s Disease (APOE4 and Familial mutations), Parkinson’s Disease (SNCA A53T, LRRK2 G2019S), and ALS/FTD (C9orf72 Repeat Expansion).